MHY1485: mTOR Activator and Autophagy Inhibitor for Advanced Cellular Research

Executive Summary: MHY1485 is a selective mTOR activator that inhibits autophagy by suppressing autophagosome-lysosome fusion (Liu et al., 2023, https://doi.org/10.1155/2023/8994901). The compound induces LC3II accumulation and autophagosome enlargement in a dose- and time-dependent manner (APExBIO). MHY1485 enhances ovarian follicle development in mouse models and is insoluble in ethanol and water but soluble in DMSO at ≥19.35 mg/mL. Its performance benchmarks are established for mTOR pathway and autophagy assays, supporting rigorous cell proliferation and survival studies. These properties make MHY1485 a reference tool in cancer biology and neurodegenerative disease research.

Biological Rationale

The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that regulates cellular metabolism, growth, and survival. mTOR signaling is central to the control of autophagy, an intracellular process responsible for the degradation and recycling of cytoplasmic components through lysosome-mediated pathways (Liu et al., 2023). Dysregulation of mTOR or autophagy is implicated in cancer, neurodegenerative diseases, and metabolic disorders. Modulators like MHY1485 enable precise interrogation of these pathways, facilitating mechanistic studies and therapeutic exploration. As an mTOR activator and autophagy inhibitor, MHY1485 is particularly useful for dissecting the interplay between cell growth and catabolic processes, as reviewed in MHY1485: An mTOR Activator for Autophagy & Ovarian Follic...; this current article provides updated mechanistic data and integration guidance for experimental workflows.

Mechanism of Action of MHY1485

MHY1485 directly activates mTOR, leading to downstream phosphorylation of target proteins involved in protein synthesis and cell proliferation. Unlike canonical mTOR activators, MHY1485 also inhibits autophagy by specifically blocking the fusion of autophagosomes with lysosomes, thereby preventing the completion of autophagic flux (APExBIO). This dual action results in the accumulation of LC3II, a marker of autophagosomes, and the formation of enlarged autophagic vesicles within treated cells. The compound’s effects are dose- and time-dependent, and its activity has been validated in multiple cell types, including Ac2F rat hepatocytes under starvation conditions.

Evidence & Benchmarks

• MHY1485 activates mTOR signaling as demonstrated by increased phosphorylation of downstream effectors such as p70S6K and 4E-BP1 (Liu et al., 2023, https://doi.org/10.1155/2023/8994901).
• The compound inhibits autophagic flux by blocking autophagosome-lysosome fusion, leading to LC3II accumulation and enlarged autophagosomes in cultured cells (APExBIO, product page).
• In juvenile mouse ovary cultures, MHY1485 supports follicular development and increases graft weights in allo-grafting models (APExBIO, product page).
• MHY1485 is insoluble in water and ethanol but dissolves in DMSO at ≥19.35 mg/mL; typical 10 mM stock solutions are stable at -20°C when protected from repeated freeze-thaw cycles (APExBIO, product page).
• In uveal melanoma cell models, mTOR activation via MHY1485 reverses autophagy induction by LINC01278, confirming specificity in mTOR pathway interrogation (Liu et al., 2023, https://doi.org/10.1155/2023/8994901).

Applications, Limits & Misconceptions

MHY1485 is validated for research in:

• Autophagy assays: Quantifying autophagic flux and dissecting block points in the autophagy pathway.
• Ovarian follicle development research: Promoting follicle maturation in mouse and grafting models.
• Cell proliferation and survival studies: Elucidating mTOR-driven responses in cancer and metabolic models.
• Cancer biology research: Modeling mTOR dysregulation and autophagy suppression in tumorigenic systems.
• Neurodegenerative disease models: Examining the impact of mTOR pathway modulation on protein aggregation and neuronal viability.

For further distinctions, refer to this review, which details broader troubleshooting and use-case selection; the present article updates molecular benchmarks and solubility data.

Common Pitfalls or Misconceptions

• Not a general mTOR activator in all species: Potency and selectivity may differ outside commonly used mammalian cell lines.
• Does not induce autophagy: MHY1485 blocks, rather than stimulates, autophagic flux, leading to LC3II accumulation.
• Insoluble in water or ethanol: Only DMSO achieves concentrations suitable for cellular assays; improper solvents result in precipitation.
• Not a therapeutic drug: MHY1485 is for research use only; clinical safety is unestablished.
• Requires proper storage: Repeated freeze-thaw cycles or storage above -20°C can degrade compound activity.

Workflow Integration & Parameters

APExBIO recommends preparing MHY1485 as a 10 mM stock solution in DMSO. The solution should be stored at -20°C and used promptly to prevent degradation. For higher concentrations, warming and sonication are advised. Typical working concentrations in cell-based assays range from 1 to 10 μM, with optimization required based on cell type and endpoint readout. MHY1485 can be applied to serum-starved cells to interrogate mTOR-driven survival or to model autophagic flux interruption, as in studies of Ac2F rat hepatocytes (APExBIO). For comparison of autophagy inhibition strategies, see this protocol summary; this article provides updated solubility guidance and QC recommendations.

Conclusion & Outlook

MHY1485 (APExBIO, SKU: B5853) is a reference-standard mTOR activator and autophagy inhibitor for advanced cell signaling and disease model studies. Its dual action and validated benchmarks support diverse applications in oncology, reproductive biology, and neurodegeneration. Ongoing research with MHY1485 continues to refine understanding of autophagy-mTOR crosstalk, providing platforms for drug discovery and molecular diagnostics (Liu et al., 2023). For ordering or detailed protocols, visit the MHY1485 product page at APExBIO.